Adult Vaccines Market By Vaccine Type (Live Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Conjugate Vaccines, DNA and RNA Vaccines), By Administration Route (Intramuscular, Subcutaneous, Oral), By Disease Target (Influenza, Pneumococcal Diseases, Hepatitis, Human Papillomavirus (HPV), Shingles), By End-Use Industry (Hospitals, Clinics, Pharmacies), and By Region; Global Insights & Forecast (2024 – 2030)

As per Intent Market Research, the Adult Vaccines Market was valued at USD 20.6 billion in 2023 and will surpass USD 32.1 billion by 2030; growing at a CAGR of 6.6% during 2024 - 2030.

The adult vaccines market has seen significant growth in recent years, driven by the increasing awareness of the importance of vaccination for preventing infectious diseases, particularly as the global population ages. Vaccines play a crucial role in protecting adults from diseases such as influenza, pneumococcal diseases, and shingles, which can have severe consequences in older populations. With rising healthcare costs and an emphasis on preventive care, adult vaccination programs are becoming a central focus in public health strategies worldwide. This growth is also supported by advancements in vaccine technology, with new and improved vaccine formulations emerging to better protect adults from infectious diseases.

The adult vaccines market is influenced by factors such as increasing government vaccination initiatives, the rising prevalence of chronic diseases, and the ongoing global health challenges like pandemics and epidemics. Additionally, innovations in vaccine delivery methods and the development of vaccines targeting a wide range of diseases are further propelling market growth. As healthcare systems continue to emphasize prevention over treatment, the adult vaccines market is expected to expand, with new vaccines for conditions like human papillomavirus (HPV), shingles, and hepatitis playing a prominent role in this trend.

Live Attenuated Vaccines Segment Is Largest Owing to High Efficacy and Long-Lasting Immunity

The live attenuated vaccines segment is the largest in the adult vaccines market, owing to their high efficacy and ability to provide long-lasting immunity. Live attenuated vaccines are made from live microorganisms that have been weakened in the laboratory so they cannot cause disease in healthy individuals but still stimulate a strong immune response. These vaccines are particularly effective for diseases such as measles, mumps, rubella, and yellow fever, offering protection that can last for many years or even a lifetime. The superior immune response triggered by live attenuated vaccines, coupled with their ability to provide prolonged immunity, makes them a preferred choice for many adult vaccination programs.

The wide acceptance of live attenuated vaccines for both routine immunization and outbreak control has solidified their position as the largest segment in the adult vaccines market. These vaccines are commonly used in mass vaccination campaigns, making them an essential tool in global public health efforts, particularly in areas with high disease burdens. As vaccine development continues to advance, live attenuated vaccines are expected to maintain their dominance due to their proven efficacy and lasting protection.

Intramuscular Administration Route Is Largest Owing to Ease of Administration and Broad Adoption

The intramuscular administration route is the largest in the adult vaccines market, owing to its ease of administration and widespread adoption in both clinical and hospital settings. Intramuscular injections are the most common method for delivering vaccines, as they allow for the vaccine to be absorbed efficiently into the bloodstream and stimulate a robust immune response. Vaccines like the flu vaccine and the hepatitis B vaccine are frequently administered via the intramuscular route, making it the preferred choice for healthcare providers. The intramuscular route also ensures a higher degree of precision and consistency in vaccine delivery, which is essential in ensuring the vaccine's efficacy.

Additionally, the intramuscular route is favored for its versatility in delivering a wide range of vaccines, from those requiring a single dose to those needing booster shots. With the broad adoption of intramuscular injections in vaccination programs worldwide, this route remains the dominant form of administration in the adult vaccines market.

Influenza Disease Target Is Largest Owing to High Incidence and Preventive Measures

Influenza is the largest disease target in the adult vaccines market, driven by its high incidence, seasonal outbreaks, and the widespread availability of vaccines. Influenza can cause significant morbidity and mortality, particularly in high-risk adult populations such as the elderly, pregnant women, and individuals with chronic health conditions. Annual vaccination campaigns have become the cornerstone of influenza prevention efforts, with governments, healthcare organizations, and pharmaceutical companies working together to ensure widespread vaccination coverage. The availability of both trivalent and quadrivalent flu vaccines, which protect against multiple strains of the virus, has contributed to the dominance of influenza as the leading disease target.

Influenza vaccines are recommended annually, particularly in high-risk groups, making them a routine part of preventive healthcare. With ongoing global vaccination initiatives aimed at reducing the burden of flu-related complications and hospitalizations, influenza will remain the largest disease target in the adult vaccines market for the foreseeable future.

Hospitals End-Use Industry Is Largest Owing to High Patient Volume and Vaccination Campaigns

The hospitals segment is the largest end-use industry in the adult vaccines market, owing to the high volume of patients seeking vaccination services in hospital settings. Hospitals are key locations for the administration of vaccines, as they provide a controlled environment with trained healthcare professionals who can ensure proper vaccine delivery and patient care. Hospitals are also central to large-scale vaccination campaigns, particularly during seasonal outbreaks of diseases like influenza. The availability of various vaccines in hospital pharmacies and the ability to administer them to both inpatient and outpatient populations contribute to hospitals being the leading end-use industry for adult vaccines.

Hospitals also play a pivotal role in vaccinating individuals with underlying health conditions, such as diabetes or heart disease, who may be more vulnerable to infectious diseases. The broad range of services offered by hospitals, coupled with the increasing focus on preventive care, ensures that hospitals will remain the largest end-use industry for adult vaccines.

North America Is Largest Region Owing to Advanced Healthcare Infrastructure and High Vaccination Rates

North America is the largest region in the adult vaccines market, owing to its advanced healthcare infrastructure, high vaccination rates, and government-led vaccination initiatives. The United States, in particular, has established comprehensive vaccination programs that encourage widespread adult vaccination against diseases like influenza, hepatitis, and shingles. Government health agencies such as the Centers for Disease Control and Prevention (CDC) provide guidelines and recommendations for adult immunization, which significantly influences vaccination uptake across the region. In addition to high vaccination rates, North America benefits from a strong healthcare infrastructure that ensures vaccines are readily available and accessible to the population.

With the ongoing push for preventive healthcare and the availability of new vaccines for emerging diseases, North America is expected to maintain its leadership in the adult vaccines market. The region's continued focus on immunization programs and advanced healthcare systems will drive the demand for adult vaccines in the coming years.

Leading Companies and Competitive Landscape

The competitive landscape of the adult vaccines market is marked by the presence of major pharmaceutical companies that dominate the market with a broad range of vaccines. Leading companies such as GlaxoSmithKline (GSK), Merck & Co., Pfizer, and Sanofi are at the forefront of vaccine development and production. These companies offer vaccines targeting a variety of diseases, including influenza, pneumococcal infections, and human papillomavirus (HPV), and continue to invest in research and development to expand their vaccine portfolios.

The market is also witnessing the entry of smaller players focused on developing specialized vaccines or targeting emerging diseases. As competition intensifies, companies are increasingly focusing on developing new and improved vaccine formulations, enhancing production capabilities, and expanding global distribution networks. The emphasis on vaccine innovation, coupled with growing public awareness of the importance of vaccination, is expected to foster a dynamic and competitive market environment in the adult vaccines sector.

Recent Developments:

• In November 2024, Pfizer announced the launch of its new flu vaccine targeting multiple strains of the virus for improved protection.
• In October 2024, Merck & Co. received approval from the FDA for its new HPV vaccine for adults aged 45 and above.
• In September 2024, GSK partnered with a global healthcare NGO to expand access to pneumococcal vaccines in low-income regions.
• In August 2024, Moderna announced the successful completion of phase 3 trials for its mRNA-based shingles vaccine.
• In July 2024, Johnson & Johnson launched a new adult hepatitis B vaccine, targeting high-risk populations.

List of Leading Companies:

• GlaxoSmithKline (GSK)
• Merck & Co., Inc.
• Pfizer Inc.
• Sanofi
• AstraZeneca
• Johnson & Johnson
• Moderna, Inc.
• Novavax, Inc.
• Bavarian Nordic
• Serum Institute of India
• Mitsubishi Tanabe Pharma Corporation
• CSL Limited
• Takeda Pharmaceutical Company Limited
• Bharat Biotech
• Sinovac Biotech Ltd.

Report Scope: